SynSmartRasayan Research Private Limited and Amporin Pharmaceuticals AG have announced a strategic collaboration to develop innovative small molecule therapeutics aimed at treating a range of serious degenerative diseases. The partnership will focus on the discovery and development of membrane-protecting compounds designed to address underlying cellular damage associated with such conditions. As part of the agreement, SynSmart will undertake the synthesis of an extensive library of novel molecules at its research facility in Mumbai.
These compounds will undergo systematic screening to identify promising candidates for further development. Based on the outcomes, the collaboration may expand into additional areas, including advanced chemistry programmes and ADME-PK (absorption, distribution, metabolism, excretion, and pharmacokinetics) studies. The broader goal is to accelerate progress toward identifying viable drug candidates for clinical development.
Saurabh Kapure, Chief Executive Officer of SynSmart, noted that the collaboration highlights the company’s ability to deliver high-quality research support with efficiency. He pointed out that SynSmart’s multi-shift laboratory operations and streamlined organisational structure enable faster execution timelines and cost advantages for global partners.
Dr Kelvin Stott, Founder and Chief Executive Officer of Amporin, stated that the collaboration is expected to significantly speed up the screening and optimisation of therapies targeting multiple degenerative conditions simultaneously. He added that the partnership will also help validate the potential of Amporin’s proprietary platform focused on restoring membrane integrity.
Amporin’s research centres on a new class of small molecule drugs that aim to repair damage in cell and mitochondrial membranes caused by misfolded proteins. By addressing this fundamental issue, the company seeks to restore normal cellular function and potentially slow, halt, or reverse disease progression. The approach has potential applications across more than 50 degenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis, and type II diabetes, as well as several rare conditions.
SynSmart operates as a specialised chemistry CRDMO, offering services such as custom synthesis and medicinal chemistry to a global client base that includes biotechnology firms and large pharmaceutical companies. The company employs over 125 chemists and has built expertise in small molecules, complex peptides, and emerging technologies including photochemistry and flow chemistry.
